An FDA oncology analysis of immune activating products and first-in-human dose selection - Concepedia

Concepedia

Publication | Closed Access

An FDA oncology analysis of immune activating products and first-in-human dose selection

51

Citations

8

References

2016

Year

Haleh Saber, Ramadevi Gudi, Michael L. Manning, Emily Wearne, John K. Leighton

Regulatory Toxicology and Pharmacology

Fda Oncology AnalysisCancer ImmunosurveillanceMedicineFirst-in-human Dose SelectionImmunologyImmune Activating ProductsImmunoeditingImmune Checkpoint InhibitorCancer TreatmentImmunotherapyOncologyCancer Research

References

	Year	Citations

Page 1